1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Polypeptide Therapeutic Solutions S L has 1 pending office action in its portfolio. This action is assigned to 1 distinct examiner. KARST, DAVID THOMAS is the busiest examiner for the company, with 1 pending office action.
Because there is only a single pending office action, the busiest examiner is the sole examiner involved in the company's current prosecution. This 1 to 1 ratio between actions and examiners highlights a focused point of contact. The data does not specify a technology area or art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KARST, DAVID THOMAS | 1 | 64.8% | +9.7% |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18291124 | STAR-SHAPED PASP-OLIGOAMINE DERIVATIVES | KARST, DAVID THOMAS | — | §112 | Non-Final OA | — | Pending | Jan 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPolypeptide Therapeutic Solutions S L has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
David Thomas Karst has the most, with 1 of Polypeptide Therapeutic Solutions S L's pending office actions.